Generex unveils positive results of Oral-lyn's Phase III trial

07/11/2011 | American City Business Journals

Two Phase III trials of Generex Biotechnology's Oral-lyn showed that the drug helped regulate blood glucose levels in patients with type 1 diabetes. The oral insulin is not linked to severe hypoglycemia, weight changes and development of insulin antibodies in patients with the disease, the company said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY